Abstract LB-155: Adherence to tumor treating fields (TTFields) in high-grade glioma patients - a single center experience

2019 ◽  
Author(s):  
Carsten Hagemann ◽  
Judith Weiland ◽  
Nadine Lilla ◽  
Thomas Linsenmann ◽  
Ralf-Ingo Ernestus ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Single Center ◽  
Tumor Treating Fields ◽  
Single Center Experience

Abstract LB-155: Adherence to tumor treating fields (TTFields) in high-grade glioma patients - a single center experience

2019 ◽  
Author(s):  
Carsten Hagemann ◽  
Judith Weiland ◽  
Nadine Lilla ◽  
Thomas Linsenmann ◽  
Ralf-Ingo Ernestus ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Single Center ◽  
Tumor Treating Fields ◽  
Single Center Experience

scholarly journals P01.045 Adherence to Tumor Treating Fields in patients with high-grade glioma - a single center experience

2018 ◽  
Vol 20 (suppl_3) ◽  
pp. iii239-iii239
Author(s):  
A Kessler ◽  
J Weiland ◽  
M Breun ◽  
T Linsenmann ◽  
R Ernestus ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Single Center ◽  
Tumor Treating Fields ◽  
Single Center Experience

scholarly journals HOUT-25. ADHERENCE TO TUMOR TREATING FIELDS IN PATIENTS WITH HIGH-GRADE GLIOMA – A SINGLE CENTER EXPERIENCE

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi118-vi118
Author(s):  
Almuth Kessler ◽  
Judith Weiland ◽  
Maria Breun ◽  
Thomas Linsenmann ◽  
Rolf-Ingo Ernestus ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Single Center ◽  
Tumor Treating Fields ◽  
Single Center Experience

High-grade glioma in children and adolescents: a single-center experience

2015 ◽  
Vol 32 (2) ◽  
pp. 291-297 ◽  
Author(s):  
Gozde Yazici ◽  
Faruk Zorlu ◽  
Mustafa Cengiz ◽  
Gokhan Ozyigit ◽  
Gulnihan Eren ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
High Grade Glioma ◽  
High Grade ◽  
Single Center ◽  
Single Center Experience

NCOG-14. REAL-WORLD RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS IN THE TREATMENT OF HIGH-GRADE GLIOMA BASED ON CHINESE POPULATION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi154-vi155
Author(s):  
Lingchao Chen ◽  
Junrui Chen ◽  
Kun Song ◽  
Jingtao Nie ◽  
Dongxiao Zhuang ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
Chinese Population ◽  
Adverse Reactions ◽  
High Grade Glioma ◽  
High Grade ◽  
Newly Diagnosed ◽  
Efficacy Data ◽  
Tumor Treating Fields ◽  
Recurrent Gbm

Abstract OBJECTIVES Tumor Treating Fields (TTFields) has been approved for the treatment of newly diagnosed and relapsed glioblastoma（GBM）in China in 2020. Only few TTFields data in Asia patients were reported. This retrospective analysis is aimed at investigating the efficacy, safety and the potential relationship with biomarkers of TTFields treatment in the real-world clinical practice of the Chinese glioma population. METHODS High-grade glioma patients who were under TTFields treatment from May 2019 to May 2021 in Shanghai Huashan Hospital were analyzed, including baseline data, efficacy data and incidence of adverse events. RESULTS Eighty-two patients (median age 51.0 [26.0 - 47.0] years) with high-grade glioma were enrolled, including 60 newly diagnosed GBM, 16 recurrent GBM, and 6 WHO grade III gliomas. The median time was 9.9 (4.6-15.7) months for follow-ups, median time for TTFields treatment was 4.3(1.1-20.35) months. The median compliance rate was 90% (40%-97%). For newly diagnosed GBM (n=60) and recurrent GBM (n=16), the 6-month PFS rate were 78.4% (95%CI: 63.9-87.6) and 46.7% (95%CI: 21.2- 67.8) respectively. The 10-month OS rate were 86.3% (95%CI: 69.6- 94.2) and 60.0% (95%CI: 12.6- 88.2) respectively. The 6-month PFS rate in the IDHw/TERTm population was 69.9% (95%CI: 45.9-84.9) and 78.3% (95%CI: 46.5-92.5) in the IDHw/TERTw patients with newly diagnosed GBM. 59(72%) patients had skin-related adverse reactions, and majority are grade 1-2 (grade 1-2, 69.5%; grade 3, 2.5%). CONCLUSIONS This is the 1st retrospective analysis done using TTFields in the treatment of high-grade gliomas in the Chinese population with the largest sample size. From our short follow up, TTFields appears good efficacy among GBM patients. The incidence of skin adverse reactions is higher comparable to published data, but mainly consisted of grade1-2. Long-term efficacy data need to be further followed-up.

scholarly journals P11.04 A single center experience in pediatric high grade gliomas (a retrospective observational study)

2017 ◽  
Vol 19 (suppl_3) ◽  
pp. iii92-iii92
Author(s):  
M. S. Elnaggar ◽  
K. F. Riad ◽  
A. A. Abdelhakeem ◽  
A. F. Elsherif
Keyword(s):  
Observational Study ◽  
Retrospective Observational Study ◽  
High Grade ◽  
Single Center ◽  
Single Center Experience ◽  
High Grade Gliomas

Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience

2009 ◽  
Vol 96 (3) ◽  
pp. 403-408 ◽  
Author(s):  
Shelly Lwu ◽  
Mark G. Hamilton ◽  
Peter A. Forsyth ◽  
J. Gregory Cairncross ◽  
Ian F. Parney
Keyword(s):  
Malignant Glioma ◽  
High Grade ◽  
Newly Diagnosed ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document